Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 14/20 | 0.51 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12315603 | 0.85 | COXFA4 (0.57) | HSP90AA1HIF1ACOXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14098880 | 0.81 | COXFA4 (0.61) | HSP90AA1HIF1ACOXFA4 | |
| SCHEMBL12315474 | 0.77 | HIF1A (0.47) | HSP90AA1HIF1AALDH1A1CYP3A4HPGD | |
| SCHEMBL13071765 | 0.77 | COXFA4 (0.68) | HSP90AA1HIF1ACOXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14666280 | 0.76 | COXFA4 (0.61) | HSP90AA1HIF1ACOXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14666009 | 0.73 | COXFA4 (0.56) | HSP90AA1HIF1ACOXFA4 | |
| SCHEMBL12315552 | 0.72 | COXFA4 (0.74) | HSP90AA1HIF1ACOXFA4 | |
| SCHEMBL14098884 | 0.72 | COXFA4 (0.56) | HSP90AA1HIF1ACOXFA4 | |
| Encecalin SCHEMBL4310132 | 0.71 | ALDH1A1 (0.68) | HSP90AA1HIF1ACOXFA4ALDH1A1CYP3A4 | |
| SCHEMBL14666129 | 0.71 | COXFA4 (0.48) | HSP90AA1HIF1ACOXFA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | HSP90AA1 1970/4885HIF1A 887/4885COXFA4 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.